Oscar Health (NYSE:OSCR) Given New $26.00 Price Target at UBS Group

Oscar Health (NYSE:OSCR) had its target price upped by UBS Group from $20.00 to $26.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. UBS Group’s target price would suggest a potential downside of 6.91% from the company’s current price.

Other analysts have also recently issued research reports about the stock. Wolfe Research started coverage on shares of Oscar Health in a research report on Tuesday, May 5th. They issued a “peer perform” rating for the company. Wells Fargo & Company set a $20.00 price target on Oscar Health and gave the stock an “equal weight” rating in a report on Thursday, June 4th. Jefferies Financial Group raised Oscar Health from an “underperform” rating to a “hold” rating and raised their price target for the stock from $10.00 to $16.00 in a research report on Monday, April 20th. Zacks Research upgraded Oscar Health from a “hold” rating to a “strong-buy” rating in a report on Monday, July 6th. Finally, Wall Street Zen upgraded Oscar Health from a “buy” rating to a “strong-buy” rating in a research report on Sunday, June 14th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $24.00.

Oscar Health Trading Up 5.2%

NYSE OSCR traded up $1.39 during trading on Friday, reaching $27.93. 10,468,402 shares of the stock traded hands, compared to its average volume of 7,348,391. Oscar Health has a fifty-two week low of $10.69 and a fifty-two week high of $33.10. The company has a quick ratio of 1.11, a current ratio of 1.11 and a debt-to-equity ratio of 0.26. The firm has a market cap of $8.42 billion, a price-to-earnings ratio of -47.34, a price-to-earnings-growth ratio of 1.53 and a beta of 2.36. The stock’s 50-day moving average price is $28.82 and its 200 day moving average price is $20.32.

Oscar Health (NYSE:OSCR) last posted its earnings results on Thursday, August 6th. The company reported $1.10 earnings per share for the quarter, topping the consensus estimate of $0.40 by $0.70. The company had revenue of $4.88 billion for the quarter, compared to analyst estimates of $4.73 billion. Oscar Health had a negative net margin of 0.30% and a negative return on equity of 3.26%. The business’s revenue for the quarter was up 70.4% compared to the same quarter last year. During the same period last year, the business posted ($0.89) earnings per share. Analysts predict that Oscar Health will post 0.63 EPS for the current year.

Insider Activity at Oscar Health

In other news, Director Mario Schlosser sold 880,000 shares of the business’s stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $29.38, for a total value of $25,854,400.00. Following the sale, the director directly owned 480,866 shares in the company, valued at $14,127,843.08. The trade was a 64.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Mark T. Bertolini sold 624,244 shares of the company’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $28.48, for a total value of $17,778,469.12. Following the transaction, the chief executive officer directly owned 7,751,570 shares of the company’s stock, valued at $220,764,713.60. This represents a 7.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 3,662,466 shares of company stock valued at $105,145,815 in the last quarter. 22.64% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Oscar Health

A number of hedge funds and other institutional investors have recently bought and sold shares of OSCR. Conway Capital Management Inc. acquired a new position in Oscar Health during the 2nd quarter worth approximately $214,000. Wedge Capital Management L L P NC acquired a new stake in shares of Oscar Health in the second quarter valued at approximately $32,855,000. Allied Private Wealth LLC bought a new stake in shares of Oscar Health in the second quarter worth $125,000. FNY Investment Advisers LLC bought a new stake in shares of Oscar Health in the second quarter worth $57,000. Finally, Assenagon Asset Management S.A. boosted its holdings in Oscar Health by 1.6% during the second quarter. Assenagon Asset Management S.A. now owns 1,247,992 shares of the company’s stock worth $35,593,000 after purchasing an additional 20,189 shares during the last quarter. Institutional investors and hedge funds own 75.70% of the company’s stock.

Key Stories Impacting Oscar Health

Here are the key news stories impacting Oscar Health this week:

• Positive Sentiment: Substantial earnings and revenue beat: Oscar reported quarterly EPS of $1.10, versus the $0.40–$0.43 analyst consensus, compared with a $0.89 loss in the year-ago quarter. Revenue rose 70.4% to $4.88 billion, exceeding estimates of approximately $4.73 billion. Oscar Health Inc. Q2 Earnings Beat Estimates
• Positive Sentiment: Profitability improved sharply: The insurer generated approximately $361 million of second-quarter profit and more than $1 billion in net income during the first half, helped by membership growth and easing medical costs. Oscar Health Reports Another Big Profit
• Positive Sentiment: Full-year outlook was raised: Oscar increased its 2026 revenue forecast to $18.7 billion–$19.0 billion, above the roughly $18.6 billion consensus estimate, and indicated $500 million–$700 million in earnings from operations with an 81.5%–82.5% medical-loss-ratio target. Oscar Health Signals 2026 Earnings Outlook
• Neutral Sentiment: The results reinforce Oscar’s improving profit-turnaround story, with technology and operational execution remaining important to managing a changing customer base. Oscar Health 2026 Profit Turnaround
• Negative Sentiment: Churn outlook pressured the shares: Management’s forecast for elevated member churn raised concerns about retention, future enrollment growth and whether the unusually strong earnings can be sustained. That concern reportedly outweighed the quarterly beat and guidance increase. Oscar Health Falls as Churn Forecast Overshadows Q2 Beat

About Oscar Health

Oscar Health, trading on the New York Stock Exchange under the ticker OSCR, is a technology-driven health insurance company headquartered in New York, New York. Founded in 2012 by Mario Schlosser, Joshua Kushner and Kevin Nazemi, the company was built with the goal of simplifying healthcare coverage and enhancing member experience. Oscar leverages a proprietary digital platform to streamline plan enrollment, claims administration and member support, distinguishing itself in the individual, family and small group insurance markets.

The company’s primary products include on-exchange individual and family medical plans under the Affordable Care Act, off-exchange plans, as well as Medicare Advantage offerings.